Research and Clinical Trials
Search Cancer Clinical Trials
Clinical Trials
New Search
| Title | Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer |
|---|---|
| Disease/Condition | Breast Adjuvant |
| Description | The purpose of this trial is to study how well giving tamoxifen citrate, anastrozole, letrozole, or exemestane with or without chemotherapy works in treating patients with invasive breast cancer. Estrogen can cause the growth of breast cancer cells. Hormone therapy, using tamoxifen citrate, may fight breast cancer by blocking the use of estrogen by the tumor cells. Aromatase inhibitors, such as anastrozole, letrozole, and exemestane, may fight breast cancer by lowering the amount of estrogen the body makes. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known whether giving tamoxifen citrate, anastrozole, letrozole, or exemestane is more effective with combination chemotherapy in treating patients with breast cancer. |
| Eligibility Criteria | To be eligible for this study, patients must meet several criteria, including but not limited to the following: * Patient must be 18 years and older * Patient has histologically confirmed invasive breast cancer |
| Principal Investigator | Christine Pellegrino, MD |
| Contact Name | Karen Fehn, RN |
| Phone | (718) 405-8446 |
| Contact Email | kfehn@montefiore.org |
| Fax | (718) 405-8230 |
| Post Date | 01/06/2011 |
| Protocol Number | 2011-225/East |
| Status | Recruiting |
| Current Trial Type | Interventional |
